These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Short-course therapy for community-acquired pneumonia in paediatric patients. Qazi S Drugs; 2005; 65(9):1179-92. PubMed ID: 15916446 [TBL] [Abstract][Full Text] [Related]
5. Duration of antimicrobial therapy in community acquired pneumonia: less is more. Pinzone MR; Cacopardo B; Abbo L; Nunnari G ScientificWorldJournal; 2014; 2014():759138. PubMed ID: 24578660 [TBL] [Abstract][Full Text] [Related]
6. Antibiotic stewardship in community-acquired pneumonia. Viasus D; Vecino-Moreno M; De La Hoz JM; Carratalà J Expert Rev Anti Infect Ther; 2017 Apr; 15(4):351-359. PubMed ID: 28002979 [TBL] [Abstract][Full Text] [Related]
7. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy. Niven DJ; Laupland KB Expert Rev Anti Infect Ther; 2009 Feb; 7(1):69-81. PubMed ID: 19622058 [TBL] [Abstract][Full Text] [Related]
8. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review. Møller Gundersen K; Nygaard Jensen J; Bjerrum L; Hansen MP Basic Clin Pharmacol Toxicol; 2019 May; 124(5):550-559. PubMed ID: 30694600 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial therapy of community-acquired pneumonia. File TM; Niederman MS Infect Dis Clin North Am; 2004 Dec; 18(4):993-1016, xi. PubMed ID: 15555836 [TBL] [Abstract][Full Text] [Related]
10. Community-acquired pneumonia: is it time to shorten the antibiotic treatment? Esposito S; Fiore M Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078 [No Abstract] [Full Text] [Related]
11. Duration of pneumonia therapy and the role of biomarkers. Kaziani K; Sotiriou A; Dimopoulos G Curr Opin Infect Dis; 2017 Apr; 30(2):221-225. PubMed ID: 28079629 [TBL] [Abstract][Full Text] [Related]
12. Shortening antibiotic duration for community acquired pneumonia. Melo L; Oliveira S Eur J Intern Med; 2018 May; 51():e21-e22. PubMed ID: 29454484 [No Abstract] [Full Text] [Related]
13. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993 [TBL] [Abstract][Full Text] [Related]
16. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866 [TBL] [Abstract][Full Text] [Related]
17. [Duration of treatment and oral administrad on of antibiotics in community acquired pneumonia]. Bernal-Vargas MA; Cortés JA Rev Chilena Infectol; 2016 Apr; 33(2):177-86. PubMed ID: 27314995 [TBL] [Abstract][Full Text] [Related]
18. Containing costs and containing bugs: are they mutually exclusive? Nicolau DP J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S12-7. PubMed ID: 19236136 [TBL] [Abstract][Full Text] [Related]
19. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747 [TBL] [Abstract][Full Text] [Related]
20. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. Uranga A; España PP; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; Tomás L; Camino J; Nuñez J; Capelastegui A JAMA Intern Med; 2016 Sep; 176(9):1257-65. PubMed ID: 27455166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]